At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 345 enrolled
Drug / intervention
Mometasone Furoate (MF) +2 moredrug
Likely dose
Mometasone Furoate (MF) 200 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of SCH 32088 vs Beclomethasone Dipropionate (Vancenase AQ) and Placebo in Seasonal Allergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating Mometasone Furoate (MF), Beclomethasone Dipropionate (BDP), and 1 other intervention for Seasonal Allergic Rhinitis. Completed, enrolled 345 participants.
Detailed Summary
The objectives of this study are to determine the safety and efficacy in seasonal allergic rhinitis of a four-week course of mometasone furoate compared to beclomethasone dipropionate or placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
19931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 1993
Primary CompletionOct 1993
Study CompletionOct 1993
First PostedFeb 2019
TodayJul 2026
First PostedFeb 26, 2019
Enrollment StartAug 23, 1993
Primary CompletionOct 8, 1993
Study CompletionOct 22, 1993
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 7.4 years ago
Interventions
Mometasone Furoate (MF)drug
Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.
Beclomethasone Dipropionate (BDP)drug
Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) \[336 mcg total dose per day\] for 4 weeks.
Placebodrug
Placebo nasal spray administered for 4 weeks.